DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Lac-Hydrin (Ammonium Lactate Topical) - Summary

 
 



LAC-HYDRIN SUMMARY

Lac-Hydrin® (ammonium lactate) Lotion 12%

Lac-Hydrin specially formulates 12% lactic acid, neutralized with ammonium hydroxide, as ammonium lactate to provide a lotion pH of 4.4-5.5.

Lac-Hydrin Cream is indicated for the treatment of dry, scaly skin (xerosis) and ichthyosis vulgaris and for temporary relief of itching associated with these conditions.


See all Lac-Hydrin indications & dosage >>

NEWS HIGHLIGHTS

Published Studies Related to Lac-Hydrin (Ammonium Lactate Topical)

A randomized, double-blind, placebo-controlled study to evaluate the efficacy in AD of liquid soap containing 12% ammonium lactate + 20% urea. [2009.12]
Atopic dermatitis (AD) is a common chronic skin disease, which mainly affects children... The liquid soap was found to be effective in patients with AD, as use of this soap in patients with stable mild to moderate AD improved the parameters studied.

An evaluation of the moisturizing and anti-itch effects of a lactic acid and pramoxine hydrochloride cream. [2004.02]
An open-label, single-center, observer-blinded, controlled trial was conducted during the winter months to evaluate the moisturizing and antipruritic effects of a unique formulation of lactic acid 12% neutralized with ammonium hydroxide and pramoxine hydrochloride (HCl) 1% in 24 women with a history of dry itchy skin...

A double-blind clinical trial comparing the efficacy and safety of pure lanolin versus ammonium lactate 12% cream for the treatment of moderate to severe foot xerosis. [2003.01]
Xerotic skin is a pattern of reaction to a variety of disorders (eg, winter xerosis, hereditary ichthyosis) with abnormalities of desquamation in common. The trial described in this article was a double-blind randomized-comparison clinical trial investigating the effect of pure lanolin versus ammonium lactate 12% cream in treating moderate to severe foot xerosis...

A comparative study of lactic acid 10% and ammonium lactate 12% lotion in the treatment of foot xerosis. [2002.03]
Xerotic skin is a pattern of reaction to a variety of disorders that have abnormalities of desquamation in common. This double-blind, randomized clinical trial investigated the effect of Lactinol (Pedinol Pharmaceuticals, Farmingdale, New York) versus Lac-Hydrin 12% (Bristol-Myers Squibb, Princeton, New Jersey) lotion in mild to moderate foot xerosis...

Clinical evaluation of 40% urea and 12% ammonium lactate in the treatment of xerosis. [2002]
BACKGROUND: Urea and ammonium lactate are used for the treatment of xerosis, with different degrees of success. This study compares the clinical effectiveness of these two agents... DISCUSSION: At day 14 of treatment, 40% urea cream was superior to 12% ammonium lactate for most of the instrumental and clinical assessments.

more studies >>

Clinical Trials Related to Lac-Hydrin (Ammonium Lactate Topical)

Peritoneal/ Serum Lactate Ratio in Relaparotomy [Recruiting]
Laparotomy performed for both emergency of elective surgery may by complicated by intrabdominal collection, anastomotic leakage, infarction and others. This conditions are able to induce peritoneal inflammation. Inflamed peritoneum are able to produce excess of lactate that we can measure by collecting fluid from peritoneal drainage.

Drainage were left in abdomen for monitoring intrabdominal condition until the passage of stool or flatus. Minimum drainage of serum is present daily also in uncomplicated post operative period.

Serum lactate relates with increased systemic anaerobic metabolism such as SIRS, sepsis and systemic hypoperfusion and it is easy to measure with a blood gas analysis.

We hypothesized that the increases of peritoneal/ serum lactate ratio could be an earlier, sensible, non-invasive, and economical marker of post surgical complications. The decision whether and when to perform a relaparotomy in secondary peritonitis is largely subjective and based on professional experience. Actually no existing scoring system aids in this decision.

The aim of this study is to demonstrate that this ratio could be and useful tool for the surgeon in this decisional process.

Comparing the Efficacy of Ultravate Ointment in Combination With Lac-Hydrin Lotion in the Treatment of Psoriasis [Recruiting]
This is an investigator-masked, randomized, parallel, clinical study comparing the efficacy of once daily versus twice daily application of Ultravate« ointment (halobetasol propionate 0. 05% ointment) in combination with Lac-Hydrin lotion (ammonium lactate topical) in the treatment of stable plaque psoriasis. 1) Phase 1: Patients will be treated for two weeks with combination therapy using Ultravate« ointment with Lac-Hydrin lotion and their psoriasis plaques will be evaluated to test efficacy of the medication. Half the subjects will be randomized to receive treatment with once a day Ultravate« ointment and twice daily Lac-Hydrin lotion; the other half of subjects will receive twice daily Ultravate« ointment with twice daily Lac-Hydrin lotion. Ultravate« ointment will be discontinued following two weeks of treatment, in compliance with its FDA indication. Phase 2: The second treatment phase will consist of a four-week observation period. Subjects will be re-randomized to either continue using twice daily Lac-Hydrin lotion, versus no treatment. The purpose of this second phase of the study is to investigate whether use of Lac-Hydrin monotherapy twice daily can minimize risk of recurrence and maximize duration of therapeutic effect. Part of this clinical study consists of the use of patient and physician satisfaction questionnaires. These questionnaires will include questions about the satisfaction with the formulation of each agent, questions about compliance with treatment, etc. Such questions could be used to demonstrate patient and physician satisfaction with each agent, with combination therapy, and to compare patient satisfaction rates among those randomized to once daily versus twice daily application of Ultravate┬« ointment. The hypothesis is that Ultravate ointment once daily in combination with Lac-Hydrin twice daily is equal in efficacy to Ultravate ointment twice daily in combination with Lac-Hydrin twice daily.

Safety of D-lactate Producing Probiotics [Recruiting]
In this study the investigators want to test the safety of D-lactate producing probiotics in babies from birth to 1 month of age. Previous data demonstrated no increase in urinary D-lactate in 4 month old infants supplemented with D-lactate producing probiotics. The primary purpose of this study is to evaluate the influence of D-lactate producing probiotics

on D-lactate excretion in young infants during the neonatal period (days 0 - 28).

Preventive Sodium Lactate and Traumatic Brain Injury [Recruiting]
The goal of this study is to evaluate the effect of preventive intravenous infusion of half molar sodium lactate on the onset of hypertensive intracranial episodes in severe head trauma. The investigators hypothesize that preventive intravenous administration of sodium lactate will decrease the number of treatments required to decrease intracranial pressure during 48 hours.

Dovitinib Lactate, Gemcitabine Hydrochloride, and Capecitabine in Treating Patients With Advanced or Metastatic Solid Tumors or Advanced Pancreatic Cancer [Recruiting]
This phase I trial is studying the side effects and best dose of dovitinib lactate when given together with gemcitabine hydrochloride and capecitabine in treating patients with advanced or metastatic solid tumors or advanced pancreatic cancer. Dovitinib lactate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine hydrochloride and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving dovitinib lactate together with combination chemotherapy may kill more tumor cells

more trials >>


PATIENT REVIEWS / RATINGS / COMMENTS

Based on a total of 1 ratings/reviews, LAC-Hydrin has an overall score of 5. The effectiveness score is 6 and the side effect score is 10. The scores are on ten point scale: 10 - best, 1 - worst.
 

LAC-Hydrin review by 31 year old male patient

  Rating
Overall rating:  
Effectiveness:   Moderately Effective
Side effects:   No Side Effects
  
Treatment Info
Condition / reason:   Extremely dry skin
Dosage & duration:   12% (dosage frequency: twice daily) for the period of 6 months
Other conditions:   None
Other drugs taken:   None
  
Reported Results
Benefits:   It was helpful in reducing the severity on my life-long extremely dry, flaky, itchy skin. It was recommended that I be certain to apply it directly after a shower, when the skin still retains some of it's moisture from the shower itself. This is true for all lotions, but seemed particularly helpful with the Lac-hydrin. Unfortunately, though it was more helpful than many lotions I've used, the benefits did not warrant the higher price of the product. Ultimately, I've found BETTER results with the much cheaper Eucerin and even Curel moisturizing lines.
Side effects:   During the 6 months during which I used the Lac-hydrin, I didn't experience any negative side-effects. I was using it during winter months, so I don't have any feedback to offer on sun-sensitivity. I didn't experience any additional skin irritation that lessened my interest in the product. I simply moved on to other products because of the price.
Comments:   The Lac-hydrin was applied topically to all parts of my body (expect my face) twice daily. My dermatologist recommended that one of the applications be directly after my shower. The skin will retain moisture from the shower for a bit, and the application of the Lac-hydrin will help to keep it there. I would reapply to dry skin again before bed.

See all LAC-Hydrin reviews / ratings >>

Page last updated: 2010-10-05

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014